Biotinylated gene therapy vectors

被引:17
作者
Barry, MA
Campos, SK
Ghosh, D
Adams, KE
Mok, H
Mercier, GT
Parrott, MB
机构
[1] Rice Univ, Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA
[2] Rice Univ, Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA
[3] Rice Univ, Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA
[4] Rice Univ, Baylor Coll Med, Dept Bioengn, Houston, TX 77030 USA
[5] Rice Univ, Baylor Coll Med, Dept Biochem & Cell Biol, Houston, TX 77030 USA
关键词
avidin; biotin; cell-targeting; chemical biotinylation; metabolic biotinylation; streptavidin; vector purification; vector-targeting; virus purification;
D O I
10.1517/14712598.3.6.925
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The avidin-biotin system is a fundamental technology in biomedicine for immunolocalisation, imaging, nucleic acid blotting and protein labelling. This technology has recently been adapted for use in gene therapy vector applications to add proteins or cell-targeting ligands to non-viral and viral vectors. Two biotinylation technologies are being used in these applications: chemical biotinylation and metabolic biotinylation. In chemical biotinylation, reactive alkylating agents couple biotin to proteins by random covalent attachment to amino acid side chains. in metabolic biotinylation, proteins are genetically engineered with a biotin acceptor peptide (BAP), such that they are covalently biotinylated by cellular biotin ligases during viral vector production. Both technologies show promise for cell-targeting in vitro and in vivo, and for ligand screening applications. Metabolic biotinylation has the added feature of allowing viruses, vectors and vaccines to be produced from cells already biotinylated, thereby allowing them to purified by affinity chromatography on monomeric avidin columns.
引用
收藏
页码:925 / 940
页数:16
相关论文
共 77 条
[1]  
ALON R, 1992, EUR J CELL BIOL, V58, P271
[2]   Role of endogenous endonucleases and tissue site in transfection and CpG-mediated immune activation after naked DNA injection [J].
Barry, ME ;
Pinto-González, D ;
Orson, FM ;
McKenzie, GJ ;
Petry, GR ;
Barry, MA .
HUMAN GENE THERAPY, 1999, 10 (15) :2461-2480
[3]   Targeting of a cholecystokinin-DNA complex to pancreatic cells in vitro and in vivo [J].
Carpenter, DS ;
Minchin, RF .
GENE THERAPY, 1998, 5 (06) :848-854
[4]   Molecular biology of biotin attachment to proteins [J].
Chapman-Smith, A ;
Cronan, JE .
JOURNAL OF NUTRITION, 1999, 129 (02) :477S-484S
[5]   Visualizing gene expression in living mammals using a bioluminescent reporter [J].
Contag, CH ;
Spilman, SD ;
Contag, PR ;
Oshiro, M ;
Eames, B ;
Dennery, P ;
Stevenson, DK ;
Benaron, DA .
PHOTOCHEMISTRY AND PHOTOBIOLOGY, 1997, 66 (04) :523-531
[6]  
CRONAN JE, 1990, J BIOL CHEM, V265, P10327
[7]   Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions [J].
Einfeld, DA ;
Schroeder, R ;
Roelvink, PW ;
Lizonova, A ;
King, CR ;
Kovesdi, I ;
Wickham, TJ .
JOURNAL OF VIROLOGY, 2001, 75 (23) :11284-11291
[8]  
Gasparri A, 1999, CANCER RES, V59, P2917
[9]   Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2 [J].
Girod, A ;
Ried, M ;
Wobus, C ;
Lahm, H ;
Leike, K ;
Kleinschmidt, J ;
Deléage, G ;
Hallek, M .
NATURE MEDICINE, 1999, 5 (09) :1052-1056
[10]   IMMUNOSPECIFIC VESICLE TARGETING FACILITATES MICROINJECTION INTO LYMPHOCYTES [J].
GODFREY, W ;
DOE, B ;
WOFSY, L .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1983, 80 (08) :2267-2271